---
created: 2025-04-13
updated: 2025-04-13T10:53
id: iCI?c!B>us
specialty: pharmaco
specialty_id: 339
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::bevacizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::19-bevacizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::12-bevacizumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::bevacizumab
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab::zanki-extra
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::7000-7999::7221
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Bevacizumab can be used to treat Wet Age-related Macular Degeneration and **Proliferative** Diabetic Retinopathy

---

# Answer
